Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1
NCT03110380Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Jun 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of bictegravir in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Percentage of Participants With HIV-1 RNA >= 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm. Started Jun 2017; status: completed.
02
Drugs
bictegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03110380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03110380.